nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—ADRA2A—type 2 diabetes mellitus	0.417	1	CbGaD
Brimonidine—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.119	0.383	CbGbCtD
Brimonidine—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.113	0.364	CbGbCtD
Brimonidine—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0787	0.253	CbGbCtD
Brimonidine—Tizanidine—ADRA2A—type 2 diabetes mellitus	0.00118	0.269	CrCbGaD
Brimonidine—Apraclonidine—ADRA2A—type 2 diabetes mellitus	0.00115	0.262	CrCbGaD
Brimonidine—Tizanidine—CYP1A2—type 2 diabetes mellitus	0.000817	0.187	CrCbGaD
Brimonidine—Clonidine—ADRA2A—type 2 diabetes mellitus	0.000574	0.131	CrCbGaD
Brimonidine—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000545	0.129	CbGeAlD
Brimonidine—AOX1—islet of Langerhans—type 2 diabetes mellitus	0.000408	0.0964	CbGeAlD
Brimonidine—Clonidine—CYP1A2—type 2 diabetes mellitus	0.000399	0.0912	CrCbGaD
Brimonidine—AOX1—nephron tubule—type 2 diabetes mellitus	0.000329	0.0776	CbGeAlD
Brimonidine—AOX1—kidney—type 2 diabetes mellitus	0.000289	0.0682	CbGeAlD
Brimonidine—AOX1—pancreas—type 2 diabetes mellitus	0.000287	0.0678	CbGeAlD
Brimonidine—AOX1—cortex of kidney—type 2 diabetes mellitus	0.000281	0.0664	CbGeAlD
Brimonidine—Clonidine—CYP3A4—type 2 diabetes mellitus	0.000264	0.0604	CrCbGaD
Brimonidine—AOX1—adipose tissue—type 2 diabetes mellitus	0.00026	0.0615	CbGeAlD
Brimonidine—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000208	0.0491	CbGeAlD
Brimonidine—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000206	0.0486	CbGeAlD
Brimonidine—ADRA2C—kidney—type 2 diabetes mellitus	0.000183	0.0431	CbGeAlD
Brimonidine—AOX1—liver—type 2 diabetes mellitus	0.000183	0.0431	CbGeAlD
Brimonidine—ADRA2C—pancreas—type 2 diabetes mellitus	0.000181	0.0428	CbGeAlD
Brimonidine—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000178	0.042	CbGeAlD
Brimonidine—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000165	0.0389	CbGeAlD
Brimonidine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000158	0.000882	CcSEcCtD
Brimonidine—Erythema—Irbesartan—type 2 diabetes mellitus	0.000157	0.000881	CcSEcCtD
Brimonidine—Vision blurred—Metformin—type 2 diabetes mellitus	0.000157	0.00088	CcSEcCtD
Brimonidine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000157	0.000879	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000156	0.000875	CcSEcCtD
Brimonidine—Chest pain—Valsartan—type 2 diabetes mellitus	0.000156	0.000873	CcSEcCtD
Brimonidine—Myalgia—Valsartan—type 2 diabetes mellitus	0.000156	0.000873	CcSEcCtD
Brimonidine—Arthralgia—Valsartan—type 2 diabetes mellitus	0.000156	0.000873	CcSEcCtD
Brimonidine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000156	0.000871	CcSEcCtD
Brimonidine—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000155	0.00087	CcSEcCtD
Brimonidine—Anxiety—Valsartan—type 2 diabetes mellitus	0.000155	0.00087	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000155	0.000867	CcSEcCtD
Brimonidine—Angiopathy—Losartan—type 2 diabetes mellitus	0.000154	0.000864	CcSEcCtD
Brimonidine—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000154	0.000863	CcSEcCtD
Brimonidine—Myalgia—Orlistat—type 2 diabetes mellitus	0.000154	0.000862	CcSEcCtD
Brimonidine—Chest pain—Orlistat—type 2 diabetes mellitus	0.000154	0.000862	CcSEcCtD
Brimonidine—Anxiety—Orlistat—type 2 diabetes mellitus	0.000154	0.000859	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000153	0.000856	CcSEcCtD
Brimonidine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000153	0.000853	CcSEcCtD
Brimonidine—Sinusitis—Ramipril—type 2 diabetes mellitus	0.000153	0.000853	CcSEcCtD
Brimonidine—Discomfort—Orlistat—type 2 diabetes mellitus	0.000152	0.000852	CcSEcCtD
Brimonidine—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000152	0.000851	CcSEcCtD
Brimonidine—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000152	0.000851	CcSEcCtD
Brimonidine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000151	0.000843	CcSEcCtD
Brimonidine—Syncope—Metformin—type 2 diabetes mellitus	0.00015	0.000837	CcSEcCtD
Brimonidine—Oedema—Valsartan—type 2 diabetes mellitus	0.00015	0.000837	CcSEcCtD
Brimonidine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000149	0.000835	CcSEcCtD
Brimonidine—Infection—Valsartan—type 2 diabetes mellitus	0.000149	0.000831	CcSEcCtD
Brimonidine—Rash—Glipizide—type 2 diabetes mellitus	0.000148	0.000831	CcSEcCtD
Brimonidine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000148	0.00083	CcSEcCtD
Brimonidine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000148	0.00083	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000148	0.00083	CcSEcCtD
Brimonidine—Erythema—Losartan—type 2 diabetes mellitus	0.000148	0.000829	CcSEcCtD
Brimonidine—Oedema—Orlistat—type 2 diabetes mellitus	0.000148	0.000827	CcSEcCtD
Brimonidine—Headache—Glipizide—type 2 diabetes mellitus	0.000148	0.000825	CcSEcCtD
Brimonidine—Palpitations—Metformin—type 2 diabetes mellitus	0.000147	0.000825	CcSEcCtD
Brimonidine—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000147	0.000824	CcSEcCtD
Brimonidine—Shock—Valsartan—type 2 diabetes mellitus	0.000147	0.000823	CcSEcCtD
Brimonidine—Infection—Orlistat—type 2 diabetes mellitus	0.000147	0.000821	CcSEcCtD
Brimonidine—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000147	0.00082	CcSEcCtD
Brimonidine—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000147	0.00082	CcSEcCtD
Brimonidine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000146	0.000818	CcSEcCtD
Brimonidine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000145	0.000813	CcSEcCtD
Brimonidine—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000145	0.000813	CcSEcCtD
Brimonidine—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000145	0.000812	CcSEcCtD
Brimonidine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000145	0.000812	CcSEcCtD
Brimonidine—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000145	0.000811	CcSEcCtD
Brimonidine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000145	0.00081	CcSEcCtD
Brimonidine—ADRA2A—pancreas—type 2 diabetes mellitus	0.000145	0.0342	CbGeAlD
Brimonidine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000145	0.000809	CcSEcCtD
Brimonidine—Hypertension—Metformin—type 2 diabetes mellitus	0.000144	0.000806	CcSEcCtD
Brimonidine—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000144	0.000803	CcSEcCtD
Brimonidine—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000143	0.000801	CcSEcCtD
Brimonidine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000142	0.000796	CcSEcCtD
Brimonidine—Myalgia—Metformin—type 2 diabetes mellitus	0.000142	0.000795	CcSEcCtD
Brimonidine—Chest pain—Metformin—type 2 diabetes mellitus	0.000142	0.000795	CcSEcCtD
Brimonidine—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000142	0.0335	CbGeAlD
Brimonidine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000141	0.000791	CcSEcCtD
Brimonidine—Syncope—Irbesartan—type 2 diabetes mellitus	0.000141	0.00079	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000141	0.000789	CcSEcCtD
Brimonidine—Visual impairment—Ramipril—type 2 diabetes mellitus	0.000141	0.000787	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000141	0.000786	CcSEcCtD
Brimonidine—Discomfort—Metformin—type 2 diabetes mellitus	0.00014	0.000785	CcSEcCtD
Brimonidine—Fatigue—Gliclazide—type 2 diabetes mellitus	0.00014	0.000785	CcSEcCtD
Brimonidine—Nausea—Glipizide—type 2 diabetes mellitus	0.00014	0.000783	CcSEcCtD
Brimonidine—Hypotension—Valsartan—type 2 diabetes mellitus	0.00014	0.000782	CcSEcCtD
Brimonidine—Vision blurred—Losartan—type 2 diabetes mellitus	0.00014	0.000781	CcSEcCtD
Brimonidine—Pain—Gliclazide—type 2 diabetes mellitus	0.000139	0.000779	CcSEcCtD
Brimonidine—Rash—Glimepiride—type 2 diabetes mellitus	0.000139	0.000775	CcSEcCtD
Brimonidine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000138	0.000775	CcSEcCtD
Brimonidine—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000138	0.000774	CcSEcCtD
Brimonidine—Rash—Sitagliptin—type 2 diabetes mellitus	0.000138	0.000773	CcSEcCtD
Brimonidine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000138	0.000772	CcSEcCtD
Brimonidine—Headache—Glimepiride—type 2 diabetes mellitus	0.000138	0.00077	CcSEcCtD
Brimonidine—Cough—Irbesartan—type 2 diabetes mellitus	0.000137	0.000769	CcSEcCtD
Brimonidine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000137	0.000768	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000136	0.000762	CcSEcCtD
Brimonidine—Oedema—Metformin—type 2 diabetes mellitus	0.000136	0.000762	CcSEcCtD
Brimonidine—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000136	0.000761	CcSEcCtD
Brimonidine—Flushing—Ramipril—type 2 diabetes mellitus	0.000135	0.000758	CcSEcCtD
Brimonidine—Infection—Metformin—type 2 diabetes mellitus	0.000135	0.000757	CcSEcCtD
Brimonidine—Insomnia—Valsartan—type 2 diabetes mellitus	0.000135	0.000757	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000135	0.000753	CcSEcCtD
Brimonidine—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000134	0.000751	CcSEcCtD
Brimonidine—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000134	0.00075	CcSEcCtD
Brimonidine—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000134	0.00075	CcSEcCtD
Brimonidine—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000134	0.00075	CcSEcCtD
Brimonidine—Shock—Metformin—type 2 diabetes mellitus	0.000134	0.000749	CcSEcCtD
Brimonidine—Insomnia—Orlistat—type 2 diabetes mellitus	0.000134	0.000748	CcSEcCtD
Brimonidine—Anxiety—Irbesartan—type 2 diabetes mellitus	0.000134	0.000747	CcSEcCtD
Brimonidine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000134	0.000747	CcSEcCtD
Brimonidine—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000134	0.000747	CcSEcCtD
Brimonidine—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000133	0.000746	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000133	0.000745	CcSEcCtD
Brimonidine—Somnolence—Valsartan—type 2 diabetes mellitus	0.000133	0.000744	CcSEcCtD
Brimonidine—Syncope—Losartan—type 2 diabetes mellitus	0.000133	0.000743	CcSEcCtD
Brimonidine—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000133	0.000742	CcSEcCtD
Brimonidine—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000132	0.000741	CcSEcCtD
Brimonidine—Skin disorder—Metformin—type 2 diabetes mellitus	0.000132	0.00074	CcSEcCtD
Brimonidine—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000132	0.000738	CcSEcCtD
Brimonidine—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000132	0.000736	CcSEcCtD
Brimonidine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000132	0.000736	CcSEcCtD
Brimonidine—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000131	0.031	CbGeAlD
Brimonidine—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000131	0.000733	CcSEcCtD
Brimonidine—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000131	0.000733	CcSEcCtD
Brimonidine—Palpitations—Losartan—type 2 diabetes mellitus	0.000131	0.000733	CcSEcCtD
Brimonidine—Nausea—Glimepiride—type 2 diabetes mellitus	0.000131	0.00073	CcSEcCtD
Brimonidine—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.00013	0.000729	CcSEcCtD
Brimonidine—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.00013	0.000729	CcSEcCtD
Brimonidine—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00013	0.000728	CcSEcCtD
Brimonidine—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.00013	0.000728	CcSEcCtD
Brimonidine—Asthenia—Glyburide—type 2 diabetes mellitus	0.00013	0.000728	CcSEcCtD
Brimonidine—Cough—Losartan—type 2 diabetes mellitus	0.000129	0.000723	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000129	0.000722	CcSEcCtD
Brimonidine—Fatigue—Valsartan—type 2 diabetes mellitus	0.000129	0.000721	CcSEcCtD
Brimonidine—Oedema—Irbesartan—type 2 diabetes mellitus	0.000128	0.000719	CcSEcCtD
Brimonidine—Pruritus—Glyburide—type 2 diabetes mellitus	0.000128	0.000717	CcSEcCtD
Brimonidine—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000128	0.000715	CcSEcCtD
Brimonidine—Infection—Irbesartan—type 2 diabetes mellitus	0.000128	0.000714	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000128	0.000714	CcSEcCtD
Brimonidine—Fatigue—Orlistat—type 2 diabetes mellitus	0.000127	0.000713	CcSEcCtD
Brimonidine—Hypotension—Metformin—type 2 diabetes mellitus	0.000127	0.000712	CcSEcCtD
Brimonidine—Erythema—Ramipril—type 2 diabetes mellitus	0.000127	0.000711	CcSEcCtD
Brimonidine—Shock—Irbesartan—type 2 diabetes mellitus	0.000126	0.000707	CcSEcCtD
Brimonidine—Pain—Orlistat—type 2 diabetes mellitus	0.000126	0.000707	CcSEcCtD
Brimonidine—Myalgia—Losartan—type 2 diabetes mellitus	0.000126	0.000706	CcSEcCtD
Brimonidine—Chest pain—Losartan—type 2 diabetes mellitus	0.000126	0.000706	CcSEcCtD
Brimonidine—Arthralgia—Losartan—type 2 diabetes mellitus	0.000126	0.000706	CcSEcCtD
Brimonidine—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000126	0.000705	CcSEcCtD
Brimonidine—Anxiety—Losartan—type 2 diabetes mellitus	0.000126	0.000703	CcSEcCtD
Brimonidine—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000125	0.000702	CcSEcCtD
Brimonidine—Rash—Bromocriptine—type 2 diabetes mellitus	0.000125	0.000699	CcSEcCtD
Brimonidine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000125	0.000699	CcSEcCtD
Brimonidine—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000125	0.000698	CcSEcCtD
Brimonidine—Discomfort—Losartan—type 2 diabetes mellitus	0.000125	0.000697	CcSEcCtD
Brimonidine—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000124	0.000696	CcSEcCtD
Brimonidine—Headache—Bromocriptine—type 2 diabetes mellitus	0.000124	0.000695	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000124	0.000694	CcSEcCtD
Brimonidine—Dry mouth—Losartan—type 2 diabetes mellitus	0.000123	0.00069	CcSEcCtD
Brimonidine—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000122	0.000684	CcSEcCtD
Brimonidine—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000121	0.000679	CcSEcCtD
Brimonidine—Somnolence—Metformin—type 2 diabetes mellitus	0.000121	0.000677	CcSEcCtD
Brimonidine—Oedema—Losartan—type 2 diabetes mellitus	0.000121	0.000677	CcSEcCtD
Brimonidine—Infection—Losartan—type 2 diabetes mellitus	0.00012	0.000672	CcSEcCtD
Brimonidine—Hypotension—Irbesartan—type 2 diabetes mellitus	0.00012	0.000672	CcSEcCtD
Brimonidine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00012	0.000671	CcSEcCtD
Brimonidine—Dyspepsia—Metformin—type 2 diabetes mellitus	0.00012	0.000671	CcSEcCtD
Brimonidine—Shock—Losartan—type 2 diabetes mellitus	0.000119	0.000666	CcSEcCtD
Brimonidine—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000119	0.000663	CcSEcCtD
Brimonidine—Tachycardia—Losartan—type 2 diabetes mellitus	0.000118	0.00066	CcSEcCtD
Brimonidine—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000118	0.000659	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000118	0.000658	CcSEcCtD
Brimonidine—Fatigue—Metformin—type 2 diabetes mellitus	0.000117	0.000657	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000117	0.000655	CcSEcCtD
Brimonidine—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000117	0.000653	CcSEcCtD
Brimonidine—ADRA2C—liver—type 2 diabetes mellitus	0.000115	0.0273	CbGeAlD
Brimonidine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000115	0.000646	CcSEcCtD
Brimonidine—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000115	0.000644	CcSEcCtD
Brimonidine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000115	0.000641	CcSEcCtD
Brimonidine—Rash—Glyburide—type 2 diabetes mellitus	0.000114	0.000639	CcSEcCtD
Brimonidine—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000114	0.000639	CcSEcCtD
Brimonidine—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000114	0.000639	CcSEcCtD
Brimonidine—Syncope—Ramipril—type 2 diabetes mellitus	0.000114	0.000637	CcSEcCtD
Brimonidine—Headache—Glyburide—type 2 diabetes mellitus	0.000114	0.000635	CcSEcCtD
Brimonidine—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000113	0.000633	CcSEcCtD
Brimonidine—Hypotension—Losartan—type 2 diabetes mellitus	0.000113	0.000632	CcSEcCtD
Brimonidine—Palpitations—Ramipril—type 2 diabetes mellitus	0.000112	0.000628	CcSEcCtD
Brimonidine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000112	0.000625	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000111	0.000621	CcSEcCtD
Brimonidine—Cough—Ramipril—type 2 diabetes mellitus	0.000111	0.00062	CcSEcCtD
Brimonidine—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000111	0.00062	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.00011	0.000616	CcSEcCtD
Brimonidine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00011	0.000616	CcSEcCtD
Brimonidine—Pain—Irbesartan—type 2 diabetes mellitus	0.00011	0.000615	CcSEcCtD
Brimonidine—Insomnia—Losartan—type 2 diabetes mellitus	0.000109	0.000612	CcSEcCtD
Brimonidine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000109	0.000609	CcSEcCtD
Brimonidine—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000109	0.000608	CcSEcCtD
Brimonidine—Myalgia—Ramipril—type 2 diabetes mellitus	0.000108	0.000605	CcSEcCtD
Brimonidine—Chest pain—Ramipril—type 2 diabetes mellitus	0.000108	0.000605	CcSEcCtD
Brimonidine—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000108	0.000605	CcSEcCtD
Brimonidine—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000108	0.000603	CcSEcCtD
Brimonidine—Anxiety—Ramipril—type 2 diabetes mellitus	0.000108	0.000603	CcSEcCtD
Brimonidine—Nausea—Glyburide—type 2 diabetes mellitus	0.000108	0.000602	CcSEcCtD
Brimonidine—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000108	0.000602	CcSEcCtD
Brimonidine—Somnolence—Losartan—type 2 diabetes mellitus	0.000108	0.000601	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000107	0.000601	CcSEcCtD
Brimonidine—Asthenia—Valsartan—type 2 diabetes mellitus	0.000107	0.0006	CcSEcCtD
Brimonidine—Discomfort—Ramipril—type 2 diabetes mellitus	0.000107	0.000598	CcSEcCtD
Brimonidine—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000106	0.000596	CcSEcCtD
Brimonidine—Asthenia—Orlistat—type 2 diabetes mellitus	0.000106	0.000593	CcSEcCtD
Brimonidine—Pruritus—Valsartan—type 2 diabetes mellitus	0.000106	0.000592	CcSEcCtD
Brimonidine—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000106	0.000592	CcSEcCtD
Brimonidine—Pruritus—Orlistat—type 2 diabetes mellitus	0.000105	0.000585	CcSEcCtD
Brimonidine—Fatigue—Losartan—type 2 diabetes mellitus	0.000104	0.000583	CcSEcCtD
Brimonidine—Oedema—Ramipril—type 2 diabetes mellitus	0.000104	0.00058	CcSEcCtD
Brimonidine—Pain—Losartan—type 2 diabetes mellitus	0.000103	0.000579	CcSEcCtD
Brimonidine—Rash—Gliclazide—type 2 diabetes mellitus	0.000103	0.000574	CcSEcCtD
Brimonidine—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000103	0.000574	CcSEcCtD
Brimonidine—Shock—Ramipril—type 2 diabetes mellitus	0.000102	0.000571	CcSEcCtD
Brimonidine—Headache—Gliclazide—type 2 diabetes mellitus	0.000102	0.00057	CcSEcCtD
Brimonidine—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000102	0.000569	CcSEcCtD
Brimonidine—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000101	0.000566	CcSEcCtD
Brimonidine—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000101	0.000563	CcSEcCtD
Brimonidine—Dizziness—Valsartan—type 2 diabetes mellitus	9.89e-05	0.000553	CcSEcCtD
Brimonidine—Dizziness—Orlistat—type 2 diabetes mellitus	9.77e-05	0.000547	CcSEcCtD
Brimonidine—Asthenia—Metformin—type 2 diabetes mellitus	9.77e-05	0.000547	CcSEcCtD
Brimonidine—Hypotension—Ramipril—type 2 diabetes mellitus	9.69e-05	0.000542	CcSEcCtD
Brimonidine—Nausea—Gliclazide—type 2 diabetes mellitus	9.67e-05	0.000541	CcSEcCtD
Brimonidine—Pruritus—Metformin—type 2 diabetes mellitus	9.63e-05	0.000539	CcSEcCtD
Brimonidine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	9.47e-05	0.00053	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	9.45e-05	0.000529	CcSEcCtD
Brimonidine—Rash—Valsartan—type 2 diabetes mellitus	9.43e-05	0.000527	CcSEcCtD
Brimonidine—Dermatitis—Valsartan—type 2 diabetes mellitus	9.42e-05	0.000527	CcSEcCtD
Brimonidine—Insomnia—Ramipril—type 2 diabetes mellitus	9.38e-05	0.000525	CcSEcCtD
Brimonidine—Headache—Valsartan—type 2 diabetes mellitus	9.37e-05	0.000524	CcSEcCtD
Brimonidine—Rash—Orlistat—type 2 diabetes mellitus	9.32e-05	0.000521	CcSEcCtD
Brimonidine—Paraesthesia—Ramipril—type 2 diabetes mellitus	9.31e-05	0.000521	CcSEcCtD
Brimonidine—Dermatitis—Orlistat—type 2 diabetes mellitus	9.31e-05	0.000521	CcSEcCtD
Brimonidine—Headache—Orlistat—type 2 diabetes mellitus	9.26e-05	0.000518	CcSEcCtD
Brimonidine—Dyspnoea—Ramipril—type 2 diabetes mellitus	9.24e-05	0.000517	CcSEcCtD
Brimonidine—Asthenia—Irbesartan—type 2 diabetes mellitus	9.22e-05	0.000516	CcSEcCtD
Brimonidine—Somnolence—Ramipril—type 2 diabetes mellitus	9.22e-05	0.000516	CcSEcCtD
Brimonidine—Dyspepsia—Ramipril—type 2 diabetes mellitus	9.13e-05	0.000511	CcSEcCtD
Brimonidine—Pruritus—Irbesartan—type 2 diabetes mellitus	9.09e-05	0.000509	CcSEcCtD
Brimonidine—Dizziness—Metformin—type 2 diabetes mellitus	9e-05	0.000504	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	8.95e-05	0.000501	CcSEcCtD
Brimonidine—Fatigue—Ramipril—type 2 diabetes mellitus	8.94e-05	0.0005	CcSEcCtD
Brimonidine—Hypersensitivity—Losartan—type 2 diabetes mellitus	8.91e-05	0.000498	CcSEcCtD
Brimonidine—Nausea—Valsartan—type 2 diabetes mellitus	8.88e-05	0.000497	CcSEcCtD
Brimonidine—Nausea—Orlistat—type 2 diabetes mellitus	8.78e-05	0.000491	CcSEcCtD
Brimonidine—Asthenia—Losartan—type 2 diabetes mellitus	8.68e-05	0.000485	CcSEcCtD
Brimonidine—Rash—Metformin—type 2 diabetes mellitus	8.59e-05	0.00048	CcSEcCtD
Brimonidine—Dermatitis—Metformin—type 2 diabetes mellitus	8.58e-05	0.00048	CcSEcCtD
Brimonidine—Pruritus—Losartan—type 2 diabetes mellitus	8.56e-05	0.000479	CcSEcCtD
Brimonidine—Headache—Metformin—type 2 diabetes mellitus	8.53e-05	0.000477	CcSEcCtD
Brimonidine—Dizziness—Irbesartan—type 2 diabetes mellitus	8.5e-05	0.000475	CcSEcCtD
Brimonidine—Rash—Irbesartan—type 2 diabetes mellitus	8.1e-05	0.000453	CcSEcCtD
Brimonidine—Dermatitis—Irbesartan—type 2 diabetes mellitus	8.09e-05	0.000453	CcSEcCtD
Brimonidine—Nausea—Metformin—type 2 diabetes mellitus	8.09e-05	0.000452	CcSEcCtD
Brimonidine—Headache—Irbesartan—type 2 diabetes mellitus	8.05e-05	0.00045	CcSEcCtD
Brimonidine—Dizziness—Losartan—type 2 diabetes mellitus	8e-05	0.000447	CcSEcCtD
Brimonidine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	7.64e-05	0.000427	CcSEcCtD
Brimonidine—Nausea—Irbesartan—type 2 diabetes mellitus	7.63e-05	0.000427	CcSEcCtD
Brimonidine—Rash—Losartan—type 2 diabetes mellitus	7.62e-05	0.000427	CcSEcCtD
Brimonidine—Dermatitis—Losartan—type 2 diabetes mellitus	7.62e-05	0.000426	CcSEcCtD
Brimonidine—Headache—Losartan—type 2 diabetes mellitus	7.58e-05	0.000424	CcSEcCtD
Brimonidine—Asthenia—Ramipril—type 2 diabetes mellitus	7.44e-05	0.000416	CcSEcCtD
Brimonidine—Pruritus—Ramipril—type 2 diabetes mellitus	7.34e-05	0.00041	CcSEcCtD
Brimonidine—Nausea—Losartan—type 2 diabetes mellitus	7.18e-05	0.000402	CcSEcCtD
Brimonidine—Dizziness—Ramipril—type 2 diabetes mellitus	6.86e-05	0.000384	CcSEcCtD
Brimonidine—Rash—Ramipril—type 2 diabetes mellitus	6.54e-05	0.000366	CcSEcCtD
Brimonidine—Dermatitis—Ramipril—type 2 diabetes mellitus	6.53e-05	0.000365	CcSEcCtD
Brimonidine—Headache—Ramipril—type 2 diabetes mellitus	6.5e-05	0.000363	CcSEcCtD
Brimonidine—Nausea—Ramipril—type 2 diabetes mellitus	6.16e-05	0.000345	CcSEcCtD
Brimonidine—AOX1—Disease—TGFB1—type 2 diabetes mellitus	1.34e-05	0.000158	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	1.33e-05	0.000156	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.33e-05	0.000156	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	1.33e-05	0.000156	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.32e-05	0.000155	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.32e-05	0.000155	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—VEGFA—type 2 diabetes mellitus	1.32e-05	0.000155	CbGpPWpGaD
Brimonidine—AOX1—Disease—EGFR—type 2 diabetes mellitus	1.32e-05	0.000155	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	1.32e-05	0.000155	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IAPP—type 2 diabetes mellitus	1.31e-05	0.000154	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—INSR—type 2 diabetes mellitus	1.3e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.3e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GNB3—type 2 diabetes mellitus	1.3e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TGFB1—type 2 diabetes mellitus	1.3e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—HMOX1—type 2 diabetes mellitus	1.29e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP2E1—type 2 diabetes mellitus	1.29e-05	0.000152	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.28e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AGT—type 2 diabetes mellitus	1.28e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TRPC6—type 2 diabetes mellitus	1.28e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SLC2A1—type 2 diabetes mellitus	1.28e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP1A2—type 2 diabetes mellitus	1.28e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.28e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CAT—type 2 diabetes mellitus	1.28e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	1.28e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AGTR2—type 2 diabetes mellitus	1.27e-05	0.000149	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.26e-05	0.000148	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GCG—type 2 diabetes mellitus	1.26e-05	0.000148	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.26e-05	0.000148	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCR5—type 2 diabetes mellitus	1.25e-05	0.000147	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CYP3A4—type 2 diabetes mellitus	1.25e-05	0.000146	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.24e-05	0.000146	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.24e-05	0.000146	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.24e-05	0.000146	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—APOB—type 2 diabetes mellitus	1.24e-05	0.000145	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.24e-05	0.000145	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—C3—type 2 diabetes mellitus	1.22e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SLC2A4—type 2 diabetes mellitus	1.22e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GCG—type 2 diabetes mellitus	1.22e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.22e-05	0.000143	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TGFB1—type 2 diabetes mellitus	1.21e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GSTM1—type 2 diabetes mellitus	1.21e-05	0.000142	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.18e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—LPL—type 2 diabetes mellitus	1.18e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.18e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.18e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.18e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.17e-05	0.000138	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.16e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.16e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.16e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ADCY5—type 2 diabetes mellitus	1.16e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.16e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GPX1—type 2 diabetes mellitus	1.15e-05	0.000136	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.15e-05	0.000135	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.15e-05	0.000135	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AVP—type 2 diabetes mellitus	1.15e-05	0.000135	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.14e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.14e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.14e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.14e-05	0.000134	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.13e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CD36—type 2 diabetes mellitus	1.12e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.12e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.12e-05	0.000131	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPP2CA—type 2 diabetes mellitus	1.11e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOB—type 2 diabetes mellitus	1.11e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.11e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.1e-05	0.00013	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—SRC—type 2 diabetes mellitus	1.1e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.1e-05	0.000129	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.09e-05	0.000128	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.09e-05	0.000128	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.08e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VEGFA—type 2 diabetes mellitus	1.07e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AVP—type 2 diabetes mellitus	1.07e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.07e-05	0.000126	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.07e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—MTHFR—type 2 diabetes mellitus	1.07e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.06e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LPL—type 2 diabetes mellitus	1.06e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.06e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GNB3—type 2 diabetes mellitus	1.06e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.05e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—HMOX1—type 2 diabetes mellitus	1.05e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARA—type 2 diabetes mellitus	1.04e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.04e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.04e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.04e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CAT—type 2 diabetes mellitus	1.04e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOB—type 2 diabetes mellitus	1.04e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.03e-05	0.000121	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.02e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.02e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.02e-05	0.00012	CbGpPWpGaD
Brimonidine—AOX1—Disease—IL6—type 2 diabetes mellitus	1.01e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AGT—type 2 diabetes mellitus	1.01e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.01e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOB—type 2 diabetes mellitus	1.01e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CALM1—type 2 diabetes mellitus	9.95e-06	0.000117	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.93e-06	0.000117	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—APOE—type 2 diabetes mellitus	9.92e-06	0.000116	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LPL—type 2 diabetes mellitus	9.89e-06	0.000116	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TGFB1—type 2 diabetes mellitus	9.84e-06	0.000116	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—APOA1—type 2 diabetes mellitus	9.8e-06	0.000115	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	9.79e-06	0.000115	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.76e-06	0.000115	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.68e-06	0.000114	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	9.61e-06	0.000113	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	9.58e-06	0.000113	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—C3—type 2 diabetes mellitus	9.53e-06	0.000112	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	9.41e-06	0.000111	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	9.41e-06	0.00011	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	9.4e-06	0.00011	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	9.37e-06	0.00011	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—type 2 diabetes mellitus	9.35e-06	0.00011	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.28e-06	0.000109	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	9.13e-06	0.000107	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.11e-06	0.000107	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.09e-06	0.000107	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.07e-06	0.000107	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AGT—type 2 diabetes mellitus	9.06e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—type 2 diabetes mellitus	9.02e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	9.01e-06	0.000106	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.91e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8.91e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—C3—type 2 diabetes mellitus	8.91e-06	0.000105	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—LEP—type 2 diabetes mellitus	8.88e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOE—type 2 diabetes mellitus	8.88e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	8.82e-06	0.000104	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.77e-06	0.000103	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	8.71e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	8.71e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	8.67e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	8.65e-06	0.000102	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARG—type 2 diabetes mellitus	8.64e-06	0.000101	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	8.63e-06	0.000101	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	8.54e-06	0.0001	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.49e-06	9.97e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	8.49e-06	9.97e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.47e-06	9.95e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—INS—type 2 diabetes mellitus	8.47e-06	9.95e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AGT—type 2 diabetes mellitus	8.46e-06	9.94e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—type 2 diabetes mellitus	8.42e-06	9.89e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	8.41e-06	9.88e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.38e-06	9.84e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.37e-06	9.83e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.32e-06	9.77e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOE—type 2 diabetes mellitus	8.29e-06	9.74e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—LEP—type 2 diabetes mellitus	8.29e-06	9.74e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.28e-06	9.72e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	8.22e-06	9.65e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.2e-06	9.62e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	8.08e-06	9.49e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	8.05e-06	9.46e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.03e-06	9.43e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	7.96e-06	9.35e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.92e-06	9.3e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.86e-06	9.24e-05	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—type 2 diabetes mellitus	7.83e-06	9.19e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.82e-06	9.18e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ALB—type 2 diabetes mellitus	7.77e-06	9.12e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—INS—type 2 diabetes mellitus	7.58e-06	8.9e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.54e-06	8.85e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.46e-06	8.76e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—NOS3—type 2 diabetes mellitus	7.43e-06	8.72e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3R1—type 2 diabetes mellitus	7.43e-06	8.72e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.4e-06	8.69e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.4e-06	8.68e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.33e-06	8.61e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.33e-06	8.61e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.3e-06	8.57e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	7.23e-06	8.49e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	7.08e-06	8.32e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	7.01e-06	8.24e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.97e-06	8.18e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.96e-06	8.18e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.9e-06	8.1e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.88e-06	8.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	6.88e-06	8.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	6.87e-06	8.07e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.85e-06	8.04e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.85e-06	8.04e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	6.84e-06	8.03e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.82e-06	8e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	6.79e-06	7.98e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.76e-06	7.94e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	6.73e-06	7.91e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	6.73e-06	7.91e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.66e-06	7.82e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.65e-06	7.81e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.65e-06	7.81e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.51e-06	7.64e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.35e-06	7.46e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	6.31e-06	7.41e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	6.26e-06	7.35e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.21e-06	7.29e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.21e-06	7.29e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	6.03e-06	7.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	6.03e-06	7.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.01e-06	7.05e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	5.85e-06	6.87e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	5.75e-06	6.76e-05	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.7e-06	6.69e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.66e-06	6.65e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.65e-06	6.63e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.61e-06	6.59e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.56e-06	6.53e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.56e-06	6.53e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.54e-06	6.5e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	5.52e-06	6.48e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.33e-06	6.26e-05	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.32e-06	6.25e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.28e-06	6.21e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.28e-06	6.2e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.27e-06	6.19e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.24e-06	6.15e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.17e-06	6.08e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.04e-06	5.92e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.04e-06	5.92e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.98e-06	5.85e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.93e-06	5.79e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.92e-06	5.78e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.83e-06	5.68e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.79e-06	5.63e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.75e-06	5.58e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	4.59e-06	5.39e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.47e-06	5.25e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.4e-06	5.16e-05	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.32e-06	5.08e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.31e-06	5.06e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.28e-06	5.03e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.26e-06	5e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.11e-06	4.82e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.05e-06	4.75e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.03e-06	4.73e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4e-06	4.7e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.93e-06	4.61e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.73e-06	4.38e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.63e-06	4.27e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	3.41e-06	4.01e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.34e-06	3.92e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.31e-06	3.89e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.27e-06	3.84e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	3.09e-06	3.63e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.06e-06	3.59e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.86e-06	3.35e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	2.77e-06	3.26e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.51e-06	2.95e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.32e-06	2.72e-05	CbGpPWpGaD
